

Daniel J Donoghue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4572040/publications.pdf>

Version: 2024-02-01

21
papers

525
citations

759233

12
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

1052
citing authors

#	ARTICLE	IF	CITATIONS
1	Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 425-449.	7.2	125
2	Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation. <i>Molecular Cancer Research</i> , 2016, 14, 458-469.	3.4	69
3	The Receptor Tyrosine Kinase FGFR4 Negatively Regulates NF-kappaB Signaling. <i>PLoS ONE</i> , 2010, 5, e14412.	2.5	51
4	Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. <i>Cytokine and Growth Factor Reviews</i> , 2020, 52, 56-67.	7.2	44
5	Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders. <i>Trends in Molecular Medicine</i> , 2017, 23, 59-79.	6.7	29
6	The atypical CDK activator Spy1 regulates the intrinsic DNA damage response and is dependent upon p53 to inhibit apoptosis. <i>Cell Cycle</i> , 2009, 8, 66-75.	2.6	28
7	Fibroblast Growth Factor Receptor 3 Interacts with and Activates TGF β 2-Activated Kinase 1 Tyrosine Phosphorylation and NF κ B Signaling in Multiple Myeloma and Bladder Cancer. <i>PLoS ONE</i> , 2014, 9, e86470.	2.5	27
8	Early Human Prostate Adenocarcinomas Harbor Androgen-Independent Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e74438.	2.5	26
9	Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling. <i>Oncotarget</i> , 2018, 9, 34306-34319.	1.8	24
10	BCR: a promiscuous fusion partner in hematopoietic disorders. <i>Oncotarget</i> , 2019, 10, 2738-2754.	1.8	22
11	Novel Lys63-linked ubiquitination of IKK β induces STAT3 signaling. <i>Cell Cycle</i> , 2014, 13, 3964-3976.	2.6	20
12	Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. <i>Haematologica</i> , 2020, 105, 1262-1273.	3.5	20
13	Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment. <i>Oncotarget</i> , 2021, 12, 22-36.	1.8	9
14	Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness. <i>Acta Neuropathologica Communications</i> , 2022, 10, 65.	5.2	8
15	Characterization of iPS87, a prostate cancer stem cell-like cell line. <i>Oncotarget</i> , 2020, 11, 1075-1084.	1.8	5
16	Tyrosine Phosphorylation Allows Integration of Multiple Signaling Inputs by IKK β . <i>PLoS ONE</i> , 2013, 8, e84497.	2.5	4
17	Typical achondroplasia secondary to a unique insertional variant of <i>FGFR3</i> with in vitro demonstration of its effect on <i>FGFR3</i> function. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 798-805.	1.2	4
18	Proteomic analysis reveals dual requirement for Grb2 and PLC β 1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation. <i>Oncotarget</i> , 2022, 13, 659-676.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Oncogenic mutations in IKK $\hat{2}$ function through global changes induced by K63-linked ubiquitination and result in autocrine stimulation. PLoS ONE, 2018, 13, e0206014.	2.5	3
20	Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors. Translational Oncology, 2020, 13, 100853.	3.7	3
21	Constitutively Activated FGFR3 Mutants Signal through PLC $\hat{3}$ - Dependent and -Independent Pathways for Hematopoietic Transformation.. Blood, 2004, 104, 1423-1423.	1.4	0